Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
Authors:
Open Access
- 29 October 2024
- journal article
- review article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (11) , e70046
Abstract
Natural killer cell engagers (NKCEs) are a specialised subset of antibodies capable of simultaneously targeting endogenous NK cells and tumour cells, generating precise and effective cytolytic responses against cancer. This review systematically explores NK engagers as a rising star in NK‐mediated immunotherapy, specifically focusing on multi‐specific engagers. It examines the diverse configuration of NKCEs and how certain biologics could be employed to boost NK activity, including activating receptor engagement and cytokine incorporation. Some challenges and future perspectives of current NKCEs therapy are also discussed, including optimising pharmacokinetics, addressing the immunosuppressive tumour microenvironment and exploring potential combinatorial approaches. By offering an in‐depth analysis of the current landscape and future trajectories of multi‐specific NKCEs in cancer treatment, this review serves as a valuable resource for understanding this promising field of immunotherapy.Highlights: Innovative NKCEs: NK cell engagers (NKCEs) represent a promising new class of immunotherapeutics targeting tumours by activating NK cells. Multi‐specific formats: The transition from bi‐specific to multi‐specific NKCEs enhances their versatility and therapeutic efficacy. Mechanisms of action: NKCEs have the potential to improve NK cell activation by engaging activating receptors and incorporating cytokines. Clinical potential: Current clinical trials demonstrate the safety and efficacy of various NKCEs across different cancer types. Future research directions: Optimising NKCE designs and exploring combination therapies are essential for overcoming challenges in cancer treatment.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC3404000)
- National Natural Science Foundation of China (82073752, 82371781)
This publication has 99 references indexed in Scilit:
- A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic CellsJournal of Immunotherapy, 2008
- NKG2D ligands in tumor immunityOncogene, 2008
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- NKG2D signaling is coupled to the interleukin 15 receptor signaling pathwayNature Immunology, 2007
- Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype inductionBlood, 2006
- Surface NK receptors and their ligands on tumor cellsSeminars in Immunology, 2006
- Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid LeukemiaJournal of Clinical Oncology, 2005
- Natural Killer Cell Signaling PathwaysScience, 2004
- Rat NKp46 activates natural killer cell cytotoxicity and is associated with FcɛRIγ and CD3ζJournal of Leukocyte Biology, 2004
- NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cellsEuropean Journal of Immunology, 1999